AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00517296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUA with seton placement if necessary
Description: Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
Study NCT00517296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUA with seton placement if necessary
Description: Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
Study NCT00517296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Patients began therapy with adalimumab using clinic standards for dosing.
Study NCT04642872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant CIMT/BIT
Description: Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.
Study NCT04642872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant CIMT/BIT
Description: Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.
Study NCT04642872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Following the usual therapy in the baby.
Study NCT04642872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Following the usual therapy in the baby.
Study NCT04642872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant cimt
Description: use of unaffected hand containment to improve the use of affected hand with unimanual activities
Study NCT02711969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate
Description: 1,000mg Apatinib mesylate p.o. qd
Study NCT03373201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: Oral capsule
Study NCT03373201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT01675479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASIK correction of hyperopic refractive errors
Description: Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
Study NCT02706132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells(MSCs)
Description: Six doses of 1\*10\^6/kg body weight MSCs are given, intravenously.
Study NCT02638480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KneeMD
Description: KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
Study NCT00106418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
Study NCT00408252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsies
Description: No intervention, only biopsy for translational project
Study NCT00408252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: no intervention
Study NCT02939612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App for stress management
Description: An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
Study NCT02174042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangning Tongluo Capsule
Description: Taken drugs 3 times a day, with each time 3 grains
Study NCT03567434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol vs. Placebo
Description: Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.
Study NCT03567434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol vs. Placebo
Description: Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.
Study NCT03933904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.
Study NCT03221192 — intervention group
Intervention type: OTHER
Intervention: VAS questionnaire
Description: VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, >3-7 (or >30-70) as moderate disease and >7-10 (or >70-100) as severe disease.
Study NCT03221192 — intervention group
Intervention type: OTHER
Intervention: SNOT-22 questionnaire
Description: SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
Study NCT03221192 — intervention group
Intervention type: OTHER
Intervention: Data capture app
Description: Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
Study NCT02390050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin tablets
Description: Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
Study NCT02390050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bexagliflozin tablets, placebo
Description: Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
Study NCT00911287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release
Description: Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
Study NCT03866161 — intervention group
Intervention type: DEVICE
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure treatment
Study NCT03912376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quest Hyperspectral Imaging System
Description: In this camera 3 sensors are combined for optimal spectral imaging. For 2D reference, and to facilitate annotating the data, a high resolution (full HD) color image, recorded with an RGB-sensor, is included with each hyperspectral dataset.
Study NCT01880528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Given PO
Study NCT01880528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00517296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Patients began therapy with adalimumab using clinic standards for dosing.
Study NCT00517296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS
Description: Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
Study NCT03377582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both interventions uses exercises
Study NCT03377582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both interventions uses exercises
Study NCT04357535 — intervention group
Intervention type: DRUG
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)
Description: ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.
Study NCT03597347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim nebulizer solution
Description: 300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
Study NCT03597347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system
Study NCT00579033 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Tactile training + sham rTMS
Description: tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
Study NCT00579033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tactile training + rTMS
Description: tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training intervention.
Description: The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition intervention
Description: Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Description: Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive intervention
Description: Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Description: Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D-vitamin intervention
Description: Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-vitamin intervention
Description: Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational intervention
Description: The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational intervention
Description: The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart failure follow up.
Description: Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
Study NCT02365155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart failure follow up.
Description: Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
Study NCT00107653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000-1200mg po daily for 48 weeks
Study NCT00107653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 micrograms sc/week for 48 weeks
Study NCT04131413 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pNGVL4aCRTE6E7L2
Description: The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).
Study NCT04392960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetaben
Description: Patients will undergo on the same day:~* 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~* standard assessment of clonal and organ disease;~* echocardiography;~* cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation.
Study NCT02515747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: elective percutaneous coronary balloon angioplasty and/or stenting
Study NCT02515747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery bypass grafting
Description: elective surgical myocardial revascularisation
Study NCT02344108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspire® Upper Airway Simulation System (Model 3028 IPG )
Description: Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
Study NCT03507257 — intervention group
Intervention type: DRUG
Intervention: Flortaucipir
Description: All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Study NCT03507257 — intervention group
Intervention type: DRUG
Intervention: Florbetaben
Description: All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
Study NCT03507257 — intervention group
Intervention type: DRUG
Intervention: Fluorodeoxyglucose
Description: All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Study NCT04160182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Conservation Work Simplification Education
Description: The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion.
Study NCT04527796 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients.~The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided.
Study NCT00505271 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity.
Study NCT06595472 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm Oil Enriched with Plant Sterols
Description: The enriched palm oil contained 52 mg/L of phytosterols, to reach the estimated intake of plant sterols in the treatment group at the level of around 2 g/day \[22\]. The phytosterols used was Vegapure 95 FF® derived from soybean derivatives containing campesterol, stigmasterol and beta-sitosterol. The oil is consumed by respondents as cooking oil.
Study NCT06595472 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Palm oil
Description: The type, composition, and physical appearance of the oil is the same as those of the intervention arm, except that it was not added plant sterol. The oil is consumed by respondents as cooking oil.
Study NCT03222635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic follow-up
Description: Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds
Study NCT03349723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162
Description: Single rising dose groups
Study NCT03349723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single rising dose groups
Study NCT03257761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03257761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study NCT00431561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP 12009 10 µM
Description: 10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
Study NCT00431561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP 12009 80 µM
Description: 80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
Study NCT00431561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide or PCV
Description: temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
Study NCT00431561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug delivery system for administration of AP 12009
Description: Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
Study NCT00431561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of Drug Delivery System
Description: Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
Study NCT03743441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-level Laser Therapy
Description: LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.
Study NCT03743441 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Low-level Laser Therapy
Description: Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
Study NCT03743441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Concentric and eccentric exercises with a total duration of approximately 20 minutes.